• The New Money
  • Posts
  • Central Banks Back Saylor, China Hoards a Military Metal, And a New Drug To Treat Vape Dependence

Central Banks Back Saylor, China Hoards a Military Metal, And a New Drug To Treat Vape Dependence

Uncovering the world’s most exciting early stage companies. Discover what’s next.

August 20, 2024

Central Banks Are Betting On Michael Saylor's Microstrategy

Microstrategy (NASDAQ: MSTR) owns more Bitcoin than any other publicly traded company in the world, with current ownership of 226,500 Bitcoins. And now, central banks are placing their bets on the company’s vision for the future, with multiple national banks and pensions funds disclosing stakes in Microstrategy in recent 13-F filings made with the Securities and Exchange Commission.

China Has Started Hoarding This Critical Military Metal

The government of China has announced they will be significant limiting the exportation of antimony for the first time ever. Antimony is a critical metal used primarily for military purposes and is an important material input for the manufacturing of grenades, ammunition and even night vision goggles. The move highlights the importance of discovering and processing new North American based supply of the metal.

The FDA Gives Breakthrough Therapy Designation For New Drug To Quit Vaping

Achieve Life Sciences (NASDAQ: ACHV) has been granted Breakthrough Therapy Designation from the FDA for cytisinicline as a potential treatment for helping individuals reduce their addiction and dependence on vaping. There are currently no approved drugs that are specifically for helping individuals quit vaping, which is becoming increasingly more relevant as the addiction rates for vaping continues to soar globally.

The Sprint

New here? Join our community of 25,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.